AmCad BioMed Corporation (TPEX:4188)
11.05
-1.10 (-9.05%)
Nov 20, 2026, 1:30 PM CST
AmCad BioMed Revenue
AmCad BioMed had revenue of 7.99M TWD in the quarter ending September 30, 2026, a decrease of -23.40%. This brings the company's total for the last twelve months to 26.16M, down -39.87% year-over-year. In the year 2025, AmCad BioMed had annual revenue of 30.44M, down -42.69%. That makes AmCad BioMed the 43,989th largest company in the world by revenue and 2,164th in Taiwan.
Revenue (ttm)
26.16M
Revenue Growth
-39.87%
P/S Ratio
26.75
Revenue / Employee
769.47K
Employees
34
Market Cap
699.83M
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full AmCad BioMed breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.44M | -22.67M | -42.69% |
| Dec 31, 2024 | 53.11M | -12.15M | -18.62% |
| Dec 31, 2023 | 65.26M | 3.63M | 5.88% |
| Dec 31, 2022 | 61.63M | -24.16M | -28.16% |
| Dec 31, 2021 | 85.79M | 21.85M | 34.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rossmax International | 3.82B |
| Cowealth Medical Holding | 2.95B |
| AViTA | 1.05B |
| Bioptik Technology Incorporation | 891.73M |
| Diamond Biotechnology | 464.63M |
| Radiant Innovation | 417.97M |
| Wiltrom | 314.12M |
| S&S Healthcare Holding | 185.52M |